---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-124907"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2022-12-06T23:59:59+00:00"
generated_at: "2026-06-21T08:46:16.196368+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CSO Francis Plat to retire Dec 31; company details etripamil commercial plan with NDA in mid-2023

## Summary
- CSO Francis Plat retires Dec 31, 2022; consulting agreement at $15k/month (Stage 1) or $300/hr (Stages 2/3).
- RAPID Phase 3 data: 64% conversion at 30 min (etripamil) vs 31% placebo; median time 17 min vs 54 min.
- NDA submission for etripamil in PSVT expected mid-2023; development in AFib-RVR also underway.
- Initial target market 600,000–900,000 patients; net price estimate $500–$1,000/Rx; cardiologists report 53% adoption.

## SEC filing metadata
- accession: 0001104659-22-124907
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2022-12-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465922124907/0001104659-22-124907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465922124907/tm2232091d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-124907
- JSON: https://secwatch.observer/filing/0001104659-22-124907.json
- Plain text: https://secwatch.observer/filing/0001104659-22-124907.txt

## Key facts
- Executive change
  Francis Plat departed as Chief Scientific Officer at Milestone Pharmaceuticals Inc..
  - Action: retire
  - Role: Chief Scientific Officer
  source text: Mr. Oliveto, the Company’s Chief Executive Officer, announced Mr. Francis Plat’s intention to retire as Chief Scientific Officer from the Company, effective December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1408443/000110465922124907/0001104659-22-124907-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.